Travoprostum , 99% , 157283-68-6
Synonym(s):
(±)-16-(m-Trifluoromethylphenoxy)tetranorprostaglandin F2;Travoprost;Travoprost solution
CAS NO.:157283-68-6
Empirical Formula: C26H35F3O6
Molecular Weight: 500.55
MDL number: MFCD03411995
EINECS: 682-028-9
Pack Size | Price | Stock | Quantity |
1mg | RMB668.80 | In Stock |
|
5mg | RMB1990.40 | In Stock |
|
50mg | RMB7040.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
alpha | D20 +14.6° (c = 1.0 in methylene chloride) |
Boiling point: | 584.8±50.0 °C(Predicted) |
Density | 1.245±0.06 g/cm3(Predicted) |
Flash point: | 17 °C |
storage temp. | Sealed in dry,Store in freezer, under -20°C |
solubility | Dichloromethane (Sparingly, Sonicated), Chloroform (Sparingy), Methanol (Sparing |
form | ethanol solution |
pka | 13.43±0.20(Predicted) |
color | Colourless to Light Beige |
BCS Class | 2 |
Stability: | Light Sensitive |
InChIKey | MKPLKVHSHYCHOC-AHTXBMBWSA-N |
CAS DataBase Reference | 157283-68-6(CAS DataBase Reference) |
Description and Uses
Travoprost was launched in the US as Travatan?, an ophthalmic solution (0.004%) administered topically for the treatment of elevated intraocular hypertension (lOP) through open-angle glaucoma, a common optic neuropathy and a leading cause of blindness. Travoprost is the isopropyl ester of (+)-fluprostenol, a new prostaglandin derivative belonging to the PGF2α, analog class. This compound can be prepared in 8 steps from a bicyclic lactone aldehyde by a Wittig alkylidenation followed, after 2 ketonic reductions, by a lactol opening to prostenoic acid while protecting and deprotecting appropriately. Travoprost is a full agonist of FP receptors with a greater affinity than PGF2α, (K1 = 52 nM). Pharmacologic studies in rabbits treated daily for a week demonstrated a significant increase of the microvascular optic nerve head blood flow without significant alterations in the systemic flow. In several placebo-controlled clinical studies with hundreds of patients suffering from open-angle glaucoma or ocular hypertension, travoprost (1 to 4 pm daily) dose-dependently reduced lOP (by about 30% at 4 pm); it was shown equal or superior to latanoprost, another prostaglandin analog (5 pm daily) or the adrenergic ~-blocker timolol (500 pm bid). In addition, travoprost was safe and well tolerated with a low incidence of conjunctival hyperaemia.
Travoprost is a selective FP prostaglandin receptor agonist used to treat glaucoma (1,2).
Safety
Symbol(GHS) | GHS02,GHS07 |
Signal word | Danger |
Hazard statements | H225-H319 |
Precautionary statements | P210-P233-P240-P241-P242-P305+P351+P338 |
Hazard Codes | F,Xi |
Risk Statements | 11-36/37/38 |
Safety Statements | 16-26-36-7 |
RIDADR | UN 1170 3/PG 2 |
WGK Germany | 1 |
HS Code | 2937500000 |